

Usage and Effectiveness of the Low Glucose Suspend Feature of the Medtronic Paradigm Veo Insulin Pump

Pratik Agrawal, M.S., John B. Welsh, M.D., Ph.D., Brian Kannard, B.S., Sina Askari, B.S., Qingqing Yang, M.S., and Francine R. Kaufman, M.D.

Abstract

Background:

Sensor-augmented insulin pumps may be programmed to suspend insulin delivery in response to hypoglycemia. The Medtronic Paradigm® Veo™ pump with automatic low glucose suspend (LGS) was released in 2009. Data from 7 months of real-world use of the system were analyzed to assess usage patterns and effectiveness of LGS.

Method:

Data from 935 patients totaling 49,867 patient days were collected; the LGS feature was on for 82% of these days. A subset of 278 subjects who used the pump for ≥ 3 months was analyzed separately; these subjects provided 28,401 patient days of data, with LGS used for 92% of the time.

Results:

The LGS threshold was most commonly set between 50 and 60 mg/dl. A total of 27,216 LGS events occurred, and 60% began in the afternoon or evening. The median duration of LGS events was 9.87 min, 45% lasted for < 5 min, and 11% lasted for > 115 min (equivalent to the full extent of the LGS event between 115 and 120 min). Among the episodes lasting for > 115 min, the mean sensor glucose (SG) was 58.8 ± 12.4 mg/dl at LGS activation (time 0), rose to 102.2 ± 52.8 mg/dl by the end of the LGS episode (when insulin delivery was automatically resumed), and was 150.1 ± 68.6 mg/dl at 240 min. In the 278-subject subgroup, LGS usage significantly reduced the number of SG readings < 50 mg/dl ($p = 0.001$) and > 300 mg/dl ($p = 0.001$).

Conclusions:

The LGS feature was on for most of the patient days in the study. Most LGS episodes lasted for < 10 min. Use of the LGS feature significantly reduced exposure to hypoglycemia. Profound hyperglycemia resulting from LGS episodes lasting > 115 min was not observed.

J Diabetes Sci Technol 2011;5(5):1137-1141

Author Affiliation: Medtronic, Inc., Northridge, California

Abbreviations: (AUC) area under the curve, (BG) blood glucose, (CGM) continuous glucose monitoring, (LGS) low glucose suspend, (SAP) sensor-augmented pump, (SD) standard deviation, (SG) sensor glucose

Keywords: hypoglycemia avoidance, low glucose suspend, pump suspension, semi-closed loop, Veo insulin pump

Corresponding Author: John B. Welsh, M.D., Ph.D., Medtronic, Inc., 18000 Devonshire St., Northridge, CA 91325; email address john.b.welsh@medtronic.com